dm+d
10568011000001108
Articles
Safety in Lactation: Drugs used for allergic conditions
22 May 2017Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Antihistamines Non-sedating antihistamines (NSA) are preferred…
Medicine Compliance Aid Stability
GrazaxALK-Abello Ltd
ALK-Abello Ltd
Grazax
Tablet 75,000units
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Very sensitive to moisture.
29 September 2015
Lactation Safety Information
-
No published evidence of safety
Components of the allergen unlikely to enter breast milk
If possible, delay desensitisation therapy until no longer breastfeeding
No adverse effects reported in breastfed infants
9 September 2021
New Medicines
Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults
Information
New molecular entity
ASIT Biotech
ASIT Biotech
Development and Regulatory status
None
Phase III Clinical Trials
None
Category
A peptide hydrolysate from Lolium perenne, consisting of highly purified natural allergen fragments. The ASIT+ allergen fragments rapidly triggers a protective immune response without need of an adjuvant. Given as 4 doses over 3 weeks.
Allergic rhinitis is a common problem, affecting over 20% of the UK population. Grass pollens usually cause symptoms from late spring to early summer. Main lines of treatment are education, allergy avoidance, antihistamines and topical steroids [1]. NHS England has estimated that ~20,000 people in England require referral to a specialist centre for severe allergy, with half of those receiving specialist interventions such as immunotherapy or investigation for drug allergy [2].
Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults
Subcutaneous injection